Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

P. E. Schwartz, J. T. Chambers, E. I. Kohorn, Setsuko K Chambers, H. Weitzman, I. M. Voynick, N. MacLusky, F. Naftolin

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist-antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis-diamminedichloroplatinum) would significantly improve survival. Fifty-one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression-free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be imappropriate.

Original languageEnglish (US)
Pages (from-to)1074-1078
Number of pages5
JournalCancer
Volume63
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Tamoxifen
Drug Therapy
Cytosol
Estrogen Antagonists
Steroid Receptors
Cytotoxins
Progesterone Receptors
Estrogen Receptors
Ovarian Neoplasms
Doxorubicin
Cisplatin
Disease-Free Survival
Neoplasms
Prospective Studies
Survival
Ovarian epithelial cancer
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schwartz, P. E., Chambers, J. T., Kohorn, E. I., Chambers, S. K., Weitzman, H., Voynick, I. M., ... Naftolin, F. (1989). Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer, 63(6), 1074-1078.

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. / Schwartz, P. E.; Chambers, J. T.; Kohorn, E. I.; Chambers, Setsuko K; Weitzman, H.; Voynick, I. M.; MacLusky, N.; Naftolin, F.

In: Cancer, Vol. 63, No. 6, 1989, p. 1074-1078.

Research output: Contribution to journalArticle

Schwartz, PE, Chambers, JT, Kohorn, EI, Chambers, SK, Weitzman, H, Voynick, IM, MacLusky, N & Naftolin, F 1989, 'Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial', Cancer, vol. 63, no. 6, pp. 1074-1078.
Schwartz, P. E. ; Chambers, J. T. ; Kohorn, E. I. ; Chambers, Setsuko K ; Weitzman, H. ; Voynick, I. M. ; MacLusky, N. ; Naftolin, F. / Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. In: Cancer. 1989 ; Vol. 63, No. 6. pp. 1074-1078.
@article{de714a02d240428db379c17b68c8899a,
title = "Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial",
abstract = "One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist-antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis-diamminedichloroplatinum) would significantly improve survival. Fifty-one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression-free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be imappropriate.",
author = "Schwartz, {P. E.} and Chambers, {J. T.} and Kohorn, {E. I.} and Chambers, {Setsuko K} and H. Weitzman and Voynick, {I. M.} and N. MacLusky and F. Naftolin",
year = "1989",
language = "English (US)",
volume = "63",
pages = "1074--1078",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

AU - Schwartz, P. E.

AU - Chambers, J. T.

AU - Kohorn, E. I.

AU - Chambers, Setsuko K

AU - Weitzman, H.

AU - Voynick, I. M.

AU - MacLusky, N.

AU - Naftolin, F.

PY - 1989

Y1 - 1989

N2 - One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist-antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis-diamminedichloroplatinum) would significantly improve survival. Fifty-one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression-free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be imappropriate.

AB - One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist-antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis-diamminedichloroplatinum) would significantly improve survival. Fifty-one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression-free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be imappropriate.

UR - http://www.scopus.com/inward/record.url?scp=0024505272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024505272&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1074

EP - 1078

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -